2020-Present Health & Well Being Hepatitis

First Global Fund to Eliminate Hepatitis

The Hepatitis Fund, Global

The Hepatitis Fund (“THF”) is a global funding organization, which has been incubated by ZeShan Foundation since 2017. Publicly known as EndHep2030, THF was officially detached from the sponsorship of Rockefeller Philanthropy Advisers (RPA) in November 2019, and registered as a non-profit organization in Geneva. By funding a variety of efforts proven most effective, THF intends to overcome the barriers that currently prevent countries from properly addressing viral hepatitis as a global public health threat – a pandemic that will kill 1.4 million people a year.

Following the 2016 Hepatitis Summit in Hong Kong, our support towards THF was part of our efforts to capstone the Hepatitis Program which has been developed since 2010.

For more details, please visit our partner’s website: https://endhep2030.org/

News

The first Global Hepatitis Resource Mobilization Conference

Funding for Eliminating Viral Hepatitis

Heading 02

Heading 02 (H3)

When an unknown printer took a galley of type and scrambled it to make a type specimen book.

Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit…Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.

When an unknown printer took a galley of type and scrambled it to make a type specimen book. It is a long established fact that a reader will be distracted by the readable content of a page when looking at its layout. The point of using Lorem Ipsum is that it has a more-or-less normal distribution of letters, as opposed to using ‘Content here, content here’, making it look like readable English. Many desktop publishing packages and web page editors now use Lorem Ipsum as their default model text, and a search for ‘lorem ipsum’ will uncover many web sites still in their infancy. Various versions have evolved over the years, sometimes by accident, sometimes on purpose (injected humour and the like).

Photos Grid for Heading 02

Tab 1
Tab 2
Tab 3

Inside Tab Heading 01 H4

It is a long established fact that a reader will be distracted by the readable content of a page when looking at its layout. The point of using Lorem Ipsum is that it has a more-or-less normal distribution of letters, as opposed to using ‘Content here, content here’, making it look like readable English. Many desktop publishing packages and web page editors now use Lorem Ipsum as their default model text, and a search for ‘lorem ipsum’ will uncover many web sites still in their infancy. Various versions have evolved over the years, sometimes by accident, sometimes on purpose (injected humour and the like).

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.

0123456789001234567890

Counter 01

Quantifying Hepatitis B and C Burden in Asia

CDA Foundation, Asia

Viral hepatitis continues to be one of the deadliest infections in the world, attributed as the cause of one death every 25 seconds, as well as being identified as the leading cause of liver cancer in the world. Most cases of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are in Asia, so it is important to quantify the disease burden in Asia to help international agencies, public health organizations and policy-makers develop strategies to eliminate these infections.

Today, there are many treatments to eliminate viral hepatitis. With the availability of vaccines that can effectively prevent Hepatitis B, many countries have adopted large-scale vaccination practices for infants, one such example being China. Treatment for Hepatitis B has also been developed for patients who had been infected prior to the availability of vaccines, and existing treatments for Hepatitis C can cure patients within the span of 12 weeks. However, many cases of HBV and HCV still remain untreated to this day.

Since 2018, the ZeShan Foundation has been providing funding to the Center for Disease Analysis Foundation in their efforts to help countries in Asia eliminate hepatitis B and C in the region. To study and publish a report on the breadth of hepatitis B and C burden across Asia, the CDA Foundation worked closely with Asian countries to collect data on the number of people infected, diagnosed, and treated. In this project, mathematical models were used to estimate the impact of viral hepatitis in Asia, the summary of which is shown below. From the data collected, an estimate of 188 million people in Asia are infected with hepatitis B (Figure 1) and another 34 million with hepatitis C (Figure 2). For more details, please view the CDA Foundation’s website: https://cdafound.org/dashboard/polaris/dashboard.html.

The compiled research reveals that a majority of global HBV- and HCV-related cases of liver cancer and liver related deaths are concentrated in Asia (Figure 3). This analysis will help Asian countries obtain more funding for the elimination of viral hepatitis, and additionally recruit support from their government to test and treat this population through HBV vaccinations.

Fig. 1 An estimate 188 million people in Asia were infected with hepatitis B

Fig. 2 34 million people in Asia were infected with hepatitis C

Fig. 3 A majority of global HBV- and HCV-related cases of liver cancer and liver related deaths are concentrated in Asia